secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioRestorative Therapies, Inc. (BRTX)
CIK:        0001505497
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001021771-24-000190
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioRestorative to present Phase 2 BRTX-100 data at spine symposium; Q3 results call Nov 13
--------------------------------------------------------------------------------

- Additional preliminary 26-52 week blinded data from Phase 2 trial of BRTX-100 for chronic lumbar disc disease to be presented on Nov 13, 2024.
- Presentation at Orthopaedic Research Society/Philadelphia Spine Research Society 7th International Spine Research Symposium, Nov 10-14.
- Company will host webcasted conference call Nov 13 at 4:30pm ET to review data, Q3 2024 financial results, and provide business update.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1505497/000102177124000190/0001021771-24-000190-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1505497/000102177124000190/brt8k11624.htm
  HTML page:      https://secwatch.observer/filing/0001021771-24-000190

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer